Furthermore, we have established the predictive signature model combining MACC1 with SPINT1 for prognosis prediction in patients with GC and other seven cancer types, which will lay a foundation for the development of new biomarkers and targeted therapies in multiple cancer types. Here, MACC1 is linked to gastric cancer.